Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

SUMATRIPTAN SUCCINATE

All products: not a benefit

Other products in the same Health Canada class (N02CC) — coverage varies; not interchangeable

  • Almotriptan (Axert): not a benefit
  • Eletriptan (Relpax): not a benefit
  • Frovatriptan (Frova): not a benefit
  • Naratriptan (Amerge): not a benefit
  • Rizatriptan (Maxalt RPD): not a benefit
  • Zolmitriptan (Zomig Rapimelt): not a benefit

1 more in the class list below

Teva-Sumatriptan DF · DIN 02286815 · 25mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-20
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Imitrex; DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. Duration of Approval: 5 years Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. 217 Sumatriptan Brand(s): Imitrex Injection DOSAGE FORM/ STRENGTH: 12 mg/mL subcutaneous injection Brand(s): Imitrex Nasal Spray DOSAGE FORM/ STRENGTH: 5 mg/dose and 20 mg/dose nasal spray For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and has documented intolerance* to an oral triptan. The following information must also be provided: • Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and • The number of attacks, duration, and severity of migraines. * The nature of intolerance or why oral sumatriptan cannot be used must be specified. Duration of Approval 5 years Renewal requests for sumatriptan may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use. Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches. EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 217, record 127, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Teva-Sumatriptan DF · DIN 02286815 Manufacturer: Teva Canada Limited; listing date 2007-06-06 Health Canada: Marketed since 2011-06-29 · brand TEVA-SUMATRIPTAN DF · ATC N02CC01 SUMATRIPTAN · form Tablet · route Oral · ingredients SUMATRIPTAN (SUMATRIPTAN SUCCINATE) 25 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77227 · Verify on the e-Formulary ↗ (DIN 02286815)

Source record
DIN 02286815: Teva-Sumatriptan DF Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200026; group id 545; item number 1472; lccId None; manufacturer id TEV Source form: Tab; strength: 25mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $8.9900; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02286815 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77227
Interchangeable products
Imitrex DF · DIN 02239738 · not recorded Jamp Sumatriptan DF · DIN 02545292 · not recorded
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (28:92 Miscellaneous Central Nervous System Drugs) and how they are covered

Matched class: 28:92 Miscellaneous Central Nervous System Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: PIZOTYLINE Some products covered without a code (check the product listing): ATOMOXETINE HCL, PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 28:92 Miscellaneous Central Nervous System Drugs

ALMOTRIPTAN

· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 6.25mg, 12.5mg · Tab

ELETRIPTAN

· 16 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 20mg, 40mg · Tab

FROVATRIPTAN SUCCINATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2.5mg · Tab

NARATRIPTAN HYDROCHLORIDE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1mg, 2.5mg · Tab

RIZATRIPTAN

· 44 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg · Orally Disintegrating Tab, Tab

ZOLMITRIPTAN

· 21 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2.5mg · Orally Disintegrating Tab, Tab

PIZOTYLINE

· 1 products · General benefit · strengths: 1mg · Tab

ATOMOXETINE HCL

· 59 products · Listed, not a benefit (5), General benefit (40), Off-Formulary Interchangeable, not an ODB benefit (14) · strengths: 10mg, 18mg, 25mg, 40mg, 60mg, 80mg, 100mg · Cap

PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE

· 28 products · General benefit (19), Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2) · strengths: 0.25mg, 0.5mg, 1mg, 1.5mg · Tab

ACAMPROSATE CALCIUM

· 1 products · Limited Use, codes 531 · strengths: 333mg · DR Tab

ENTACAPONE

· 4 products · Limited Use, codes 367 · strengths: 200mg · Tab

DIMETHYL FUMARATE

· 18 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 120mg, 240mg · DR Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:92 and 1 more
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:12 Anticonvulsants, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: migraine attacks with or without aura
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. ALMOTRIPTAN · Off-Formulary Interchangeable, not an ODB benefit INDICATIONS AND CLINICAL USE Adults (> 18 years of age) MYLAN-ALMOTRIPTAN (almotriptan malate) tablets are indicated for the acute treatment of migraine attacks with or without aura. PM: https://pdf.hres.ca/dpd_pm/00035358.PDF; date June 15, 2016; DIN 02398435; fetched 2026-09-10 Product monograph FROVATRIPTAN SUCCINATE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS FROVA (frovatriptan tablets) is indicated for the acute treatment of migraine attacks with or without aura in adults. PM: https://pdf.hres.ca/dpd_pm/00084598.PDF; date SEP 03, 2004; DIN 02257084; fetched 2026-09-10 Product monograph NARATRIPTAN HYDROCHLORIDE · Off-Formulary Interchangeable, not an ODB benefit INDICATIONS AND CLINICAL USE TEVA-NARATRIPTAN (naratriptan hydrochloride) Tablets are indicated for the acute treatment of migraine attacks with or without aura in adults. PM: https://pdf.hres.ca/dpd_pm/00038181.PDF; date February 7, 2017; DIN 02314290; fetched 2026-09-10 Product monograph ZOLMITRIPTAN · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS ZOMIG (zolmitriptan; tablets, orally disintegrating tablets, nasal spray) is indicated for: • the acute treatment of migraine attacks with or without aura, in adults. PM: https://pdf.hres.ca/dpd_pm/00078682.PDF; date Aug 24, 1998; DIN 02238660; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1. Indications IMITREX DF (sumatriptan succinate) and IMITREX (sumatriptan succinate/sumatriptan hemisulphate) are indicated for the acute treatment of migraine attacks with or without aura. IMITREX DF and IMITREX are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic, basilar, or ophthalmoplegic migraine (see 2 Contraindications). Safety and efficacy have not been established for cluster headache, which is present in an older, predominantly male population. 1.1. Pediatrics Pediatrics (< 18 years of age): The safety and efficacy of IMITREX DF and IMITREX in pediatrics patients have not been established and their use in this age group is not recommended (See 7.1.3 Pediatrics). 1.2. Geriatrics Geriatrics (> 65 years of age): Experience of the use of IMITREX DF and IMITREX in patients aged over 65 years is limited. Therefore, the use of IMITREX DF and IMITREX in patients over 65 years is not recommended (See 7.1.4 Geriatrics). https://pdf.hres.ca/dpd_pm/00082699.PDF PM date: DEC 09, 2025 Source product: IMITREX DF - TAB 100MG; DIN 02212161; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Prepare an Exceptional Access request

SADIE has its own form for many drugs; this checklist prepares the answers; the ministry decides. Open SADIE

Use this text in SADIE’s free-text fields or read from it on a Telephone Request Service call. Review marks do not indicate eligibility. Evidence stays in this page until you copy it; nothing entered here is sent or saved. Do not enter patient identifiers.

EAP Telephone Request Service: The TRS can be accessed by calling toll-free at 1-866-811-9893 or 416-327-8109 (Toronto area) between 8:30 a.m. and 5:00 p.m. Monday through Friday (except holidays) and selecting the TRS option. Source; updated September 15, 2026

EAP fax: In Ontario: 1-866-811-9908 or 416-327-7526 (Toronto area). Outside Ontario: 1-833-905-4260. Source; updated September 15, 2026

Posted turnaround and Telephone Request Service scope
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
Source; updated September 15, 2026

Sumatriptan (Imitrex)

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Prepare answers: For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided:

Ministry criteria corpus 2025-01-01; page 217

Almotriptan Brand(s): Axert DOSAGE FORM/ STRENGTH: 6 mg, 12.5mg tablet
Naratriptan Brand(s): Amerge DOSAGE FORM/ STRENGTH: 1 mg, 2.5 mg tablet
Rizatriptan Brand(s): Maxalt, Maxalt RPD DOSAGE FORM/ STRENGTH: 5 mg, 10 mg tablet and wafer
Sumatriptan Brand(s): Imitrex DOSAGE FORM/ STRENGTH: 50 mg, 100 mg tablet
For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and where the following information is provided:
• Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and
• The number of attacks, duration, and severity of migraines.
Duration of Approval: 5 years
Renewal requests may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use.
Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches.
217 Sumatriptan Brand(s): Imitrex Injection DOSAGE FORM/ STRENGTH: 12 mg/mL subcutaneous injection
Brand(s): Imitrex Nasal Spray DOSAGE FORM/ STRENGTH: 5 mg/dose and 20 mg/dose nasal spray
For the treatment of migraines with or without aura in patients who failed adequate trials of other medications for migraines (e.g. acetaminophen, NSAIDs) and has documented intolerance* to an oral triptan. The following information must also be provided:
• Details of migraine prophylactic regimens (e.g. amitriptyline, beta-blockers) tried or rationale why they are inappropriate; and
• The number of attacks, duration, and severity of migraines.
* The nature of intolerance or why oral sumatriptan cannot be used must be specified.
Duration of Approval 5 years
Renewal requests for sumatriptan may be considered for patients who continue to benefit from treatment. The physician must provide the frequency of triptan use.
Warning: The frequent use of triptans (i.e. more than three days per week for longer than three months at a time) may predispose a patient to developing triptan-induced chronic daily headaches.

Prepared from the ministry's published criteria; eligibility is decided by the Exceptional Access Program.

Other review policies

For Teva-Sumatriptan DF: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026